Cancer Research Trials with BIO30 New Zealand Propolis

Professor Hiroshi Maruta has been a leading figure in several cancer research trials using BIO30 Propolis.

Professor Maruta has spent more than 35 years researching cancer and has worked for the last 20 years at the Ludwig Cancer Research Institute at the Royal Melbourne Hospital in Australia.

His work with CAPE was conducted while he was at the University Medical Hospital, Eppendorf, Germany.

Professor Maruta led research into the use of caffeic acid phenethyl ester (CAPE) in BIO30 Propolis in the treatment of neurofibromatosis (NF).

Currently there are no drugs available to treat NF, a rare genetic disease often associated with tumors in the brain, along the spinal cord and on the skin. Around 2 million people worldwide suffer from NF.

Professor Maruta’s research team conducted three trials using BIO30 Propolis.

In the first two trials mice were injected with either NF1 or NF2 tumor cells. The tumors grew, with the control group in each case not surviving.

In contrast, after about 30 days the mice treated with BIO30 Propolis Liquid all survived with the tumors not growing further than when treatment commenced.

The third trial of BIO30 Propolis began with 70 human volunteers, subsequently joined by many more. Each suffered either from NF or from formidable cancers such as melanoma or pancreatic cancer. All were treated with Bio 30 Propolis Liquid.

After 12 months the starting group returned to their specialists for MRI scans and reported no growth in the number or size of tumors. Many had shrunk or disappeared. Several patients diagnosed as terminal survived.

Professor Maruta has also conducted a parallel study with the ARC compound in Brazilian green propolis. Similar results were found in the mice study.

However, Professor Maruta says the CAPE in BIO30 Propolis is the most powerful of the natural anti-PAK compounds he has studied.
“So far the most potent of them has turned out to be CAPE (caffeic acid phenethyl ester), a rich water-miscible extract of New Zealand propolis called BIO30 which completely suppressed the growth of NF tumors (both NF1 and NF2) xenografts in mice by blocking PAK1 signalling.”

Professor Maruta has indicated CAPE is three times more effective than ARC due to the synergistic benefits of other compounds in BIO30 Propolis.

Professor Maruta indicates the synergistic effect is potentiated by around 600 times with other anti-cancer ingredients in the extract of BIO30 Propolis. Although CAPE alone has been shown to have anti-cancer activity, its bioavailability is poor in vivo and therefore it has never been used in clinical trials.

“Although CAPE alone has never been used clinically, due to its poor bioavailability/water-solubility, BIO30 Propolis contains plenty of lipids which solubilize CAPE, and also includes several other anticancer ingredients that seem to act synergistically with CAPE,” the research summary says.